3 top healthcare shares I would buy this week

Over the last 12 months the healthcare sector has been one of the best places to invest.

During this time the S&P/ASX 200 Health Care index has put on an impressive gain of 38% compared to a 9.3% gain by the benchmark S&P/ASX 200.

While I would be surprised if the healthcare sector continued this level of outperformance over the next 12 months, I still feel it has the potential to provide market-beating returns.

With that in mind, here are three top healthcare shares I would buy:

Cochlear Limited (ASX: COH)

I think that this hearing solutions specialist is one of the highest quality companies on the local market. In August the company continued its strong run of profit growth when it posted a 10% increase in net profit after tax to $245.8 million. I expect similarly solid growth in FY 2019 and beyond thanks to its exposure to the ageing populations trend. As populations around the world get older, demand for hearing products is expected to increase. And as Cochlear’s industry-leading products are sold in over 100 countries worldwide, I feel it is well-positioned to capture this growing demand.

CSL Limited (ASX: CSL)

Another company I rated incredibly highly is CSL. The global biotech star has been a consistently strong performer over the long term and shows no signs of breaking the trend in the near term. During earnings season CSL released yet another stellar full year result when it posted a 15% increase in revenue to US$7,600 million and a 29% jump in net profit after tax to US$1,730 million. Management appears confident that its positive performance will continue in FY 2019 and has provided guidance of net profit after tax in the range of US$1,880 million to US$1,950 million.

ResMed Inc. (ASX: RMD)

ResMed is a leading sleep treatment company and a great buy and hold option in my opinion. Like Cochlear and CSL, it has a long track record of solid earnings growth and didn’t disappoint in FY 2018. It posted a 13% increase in revenue to US$2.3 billion and a 27% lift in income from operations to US$541.8 million. Thanks to the positive outlook for the sleep treatment market and its focus on the fast-growing cloud-connected medical device market, I feel confident there will be more of the same in FY 2019 and beyond.

And finally, whilst this top share isn't in the healthcare sector, I believe it has just as bright growth prospects as the shares above.

Top Australian Stock Picker Just Issued Rare “Double Down” Buy Alert

Discover why this legendary Australian stock-picker just issued a “Double Down” buy alert to his exclusive group of insiders… and why he’s convinced this might be the single most attractive entry point for years to come.

Simply click here to get started and access our secure sign-up page.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!